Key result
Cancer, especially metastatic lung cancer, is linked to higher CVD mortality than the general population.
Why the study?
What are the cardiovascular disease mortality patterns among people with cancer compared to the general population?
Cohort (n=873,344)
What are the cardiovascular disease mortality patterns among people with cancer compared to the general population?
Cancer patients have a higher than expected cardiovascular disease mortality within the first few years after diagnosis, particularly those with lung cancer or distant metastases, highlighting the need for early cardiovascular risk assessment and care.
Warrants early cardio-oncology surveillance after cancer diagnosis; supports prevention trials targeting lung cancer with distant metastases.
OBJECTIVE: To investigate cardiovascular disease (CVD) mortality patterns among people with cancer in New South Wales (NSW) compared to the NSW general population and trends over time. DESIGN: Population-wide retrospective data-linkage study. PARTICIPANTS AND SETTING: 873,344 people aged ≥ 40 diagnosed with primary invasive cancer and registered in the NSW Cancer Registry between 1985 and 2019. MAIN OUTCOMES: CVD as the underlying cause of death. Absolute mortality rate (AMR, per 10,000 person-years) and standardised mortality ratios (SMR) compared to the NSW general population. RESULTS: Of 514,865 people with cancer who died between 1985 and 2020, 71% (n = 303,770) died from cancer and while 14% (n = 73,733) from CVD. AMR of CVD increased with time since cancer diagnosis (≤ 2 years: AMR = 124 vs. > 10 years: AMR = 152) and declined from 188 in 1985-1995 to 68 in 2010-2020 following cancer diagnosis in 1985-1989 and 2010-2014, respectively. Approximately 45% of CVD deaths were due to ischaemic heart disease, with 49% in males versus 40% in females. Elevated SMRs of CVD were found for ≤ 2 years after cancer diagnosis (SMR = 1.17, 95% CI: 1.15, 1.19), those aged 40-59 (SMR = 1.13, 95% CI: 1.07, 1.19) and those diagnosed with distant metastases (SMR = 1.31, 95% CI: 1.27, 1.35) or lung cancer (SMR = 1.42, 95% CI: 1.37, 1.47). Lower CVD SMRs were observed for > 2 years after cancer diagnosis (e.g., for 2-5 years: SMR = 0.84, 95% CI: 0.83, 0.86), among people diagnosed with cancers with higher survival rates (e.g., Melanoma: SMR = 0.79, 95% CI: 0.78, 0.81) and in the most recent period 2010-2020 (SMR = 0.85, 95% CI: 0.83, 0.87). CONCLUSION: Higher than expected CVD mortality compared to the general population was observed within the first few years after cancer diagnosis, especially among those diagnosed with lung cancer and distant metastases, which might reflect shared risk factors and cardiotoxic treatment. Our findings underscore the need for CVD risk assessment, prevention, and care among people with cancer.
No takes yet. Share an insight, caveat, or question.
Rahman et al. (2026) conducted a cohort in Cancer (n=873,344). Primary invasive cancer vs. New South Wales general population was evaluated on Cardiovascular disease as the underlying cause of death (SMR 1.17, 95% CI 1.15-1.19). People with cancer had higher cardiovascular disease mortality than the general population within 2 years of diagnosis (SMR 1.17; 95% CI 1.15-1.19), particularly those with lung cancer or metastases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: